biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
![Lineage Cell Therapeutics logo](/files/LOGO/876343-LCTX.png)
Company profile
Ticker
LCTX
Exchange
Website
CEO
Brian Culley
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
BIOTIME INC
SEC CIK
Corporate docs
Subsidiaries
Cell Cure Neurosciences Ltd • ES Cell International Pte. Ltd ...
IRS number
943127919
LCTX stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
14 Jun 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Jun 24
EFFECT
Notice of effectiveness
15 May 24
8-K
Other Events
14 May 24
424B5
Prospectus supplement for primary offering
14 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
9 May 24
ARS
2024 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
Transcripts
LCTX
Earnings call transcript
2024 Q1
9 May 24
LCTX
Earnings call transcript
2023 Q4
7 Mar 24
LCTX
Earnings call transcript
2023 Q3
9 Nov 23
LCTX
Earnings call transcript
2023 Q2
10 Aug 23
LCTX
Earnings call transcript
2023 Q2
10 Aug 23
LCTX
Earnings call transcript
2023 Q1
11 May 23
LCTX
Earnings call transcript
2022 Q4
9 Mar 23
LCTX
Earnings call transcript
2022 Q3
11 Nov 22
LCTX
Earnings call transcript
2022 Q2
12 Aug 22
LCTX
Earnings call transcript
2022 Q1
13 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.12 mm | 44.12 mm | 44.12 mm | 44.12 mm | 44.12 mm | 44.12 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.22 mm | 2.12 mm | 1.93 mm | 1.93 mm |
Cash used (since last report) | n/a | n/a | 8.58 mm | 8.18 mm | 7.45 mm | 7.44 mm |
Cash remaining | n/a | n/a | 35.54 mm | 35.94 mm | 36.67 mm | 36.68 mm |
Runway (months of cash) | n/a | n/a | 16.0 | 17.0 | 19.0 | 19.0 |
Institutional ownership, Q1 2024
25.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 24 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 8.63 bn |
Total shares | 47.53 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Broadwood Partners | 41.67 mm | $46.25 mm |
Defender Capital | 4.97 mm | $7.35 bn |
BK Bank Of New York Mellon | 321.20 k | $475.37 mm |
Williams Jones Wealth Management | 101.30 k | $149.92 mm |
HighTower Advisors | 63.97 k | $95.00 mm |
Commonwealth Equity Services | 47.76 k | $71.00 k |
Susquehanna International | 35.31 k | $52.25 mm |
Trust Co Of Toledo Na | 33.80 k | $50.02 mm |
Victory Capital Management | 24.67 k | $36.51 mm |
ProShare Advisors | 23.84 k | $35.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | Bradsher Neal C | OPTION TO PURCHASE COMMON SHARES COMMON SHARES | Grant | Acquire A | No | No | 0.9541 | 75,000 | 71.56 k | 75,000 |
1 Jul 24 | Bailey Don M | Stock Option Common Shares | Grant | Acquire A | No | No | 0.9541 | 75,000 | 71.56 k | 75,000 |
1 Jul 24 | Anula Jayasuriya | Stock Option Common Shares | Grant | Acquire A | No | No | 0.9541 | 75,000 | 71.56 k | 75,000 |
1 Jul 24 | Andrews Deborah J | Stock Option Common Shares | Grant | Acquire A | No | No | 0.9541 | 75,000 | 71.56 k | 75,000 |
1 Jul 24 | Dipti Amin | Stock Option Common Shares | Grant | Acquire A | No | No | 0.9541 | 75,000 | 71.56 k | 75,000 |
News
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
9 May 24
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
6 May 24
Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
6 May 24
Press releases
Lineage to Present at 2024 BIO International Convention
30 May 24
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
21 May 24
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
6 May 24
Lineage Announces Changes to Board of Directors
29 Apr 24